GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
Phase 1
Completed
- Conditions
- Heart Failure, Congestive
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02925546
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: FF/UMEC/VI (100/31.25/25) mcgDrug: FF/UMEC/VI (100/62.5/25) mcgDrug: FF/UMEC/VI (200/31.25/25) mcgDrug: FF/UMEC/VI (200/62.5/25) mcgDrug: FF/VI (100/25) mcgDrug: FF/VI (200/25) mcgDrug: Fluticasone/salmeterol (FSC)Drug: Albuterol/salbutamolDevice: ELLIPTA DPIDevice: DISKUS DPIDevice: METERED-DOSE INHALER (MDI)
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2436
- Registration Number
- NCT02924688
- Locations
- π¬π§
GSK Investigational Site, Trowbridge, United Kingdom
The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity (DH)
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Other: Stannous fluorideOther: Sodium monofluorophosphate
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 205
- Registration Number
- NCT02924350
- Locations
- π¬π§
GSK Investigational Site, Bristol, United Kingdom
To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH)
Phase 4
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Other: Stannous fluorideOther: Sodium monofluorophosphate
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 197
- Registration Number
- NCT02923895
- Locations
- π¨π¦
GSK Investigational Site, Mississauga, Ontario, Canada
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Phase 3
Completed
- Conditions
- Rotavirus VaccinesInfections, Rotavirus
- Interventions
- Biological: HRV PCV-free liquid vaccineBiological: Rotarix
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1612
- Registration Number
- NCT02914184
- Locations
- π¨π³
GSK Investigational Site, Taoyuan, Taiwan
Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants
Phase 4
Completed
- Conditions
- Rotavirus
- Interventions
- Biological: SquarekidsBiological: Rotarix
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 292
- Registration Number
- NCT02907216
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
GSK2982772 Study in Subjects With Ulcerative Colitis
Phase 2
Completed
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: PlaceboDrug: GSK2982772
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT02903966
- Locations
- π¬π§
GSK Investigational Site, Dudley, United Kingdom
Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B
Phase 4
Completed
- Conditions
- Hepatitis B Vaccine
- Interventions
- Biological: Engerix-B
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 106
- Registration Number
- NCT02901951
- Locations
- π¨π¦
GSK Investigational Site, Sherbrooke, Quebec, Canada
A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts
Not Applicable
Completed
- Conditions
- Autoimmune Diseases
- Interventions
- Radiation: 18F-FDG PET/CT ImagingProcedure: MRI Imaging with intravenous contrast with gadoterate meglumineRadiation: 11C-MET PET/CT ImagingProcedure: Minor Salivary gland (labial) biopsy
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT02899377
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
Phase 3
Withdrawn
- Conditions
- Polymyalgia Rheumatica
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02899026
Β© Copyright 2025. All Rights Reserved by MedPath